apatinib and Venous-Thrombosis

The aims of the study were to compare the efficacy and safety between transcatheter arterial chemoembolization (TACE) combined with. We retrospectively evaluated the medical records of consecutive patients with HCC-PVTT who had undergone treatment with either TACE-. The response was assessed at the last follow-up, and the outcomes were compared between the two groups. Progression-free survival (PFS), overall survival (OS), and treatment-related complications were evaluated. Statistical analysis used the 2-sample Student's t-test and Fisher's exact test.. This study enrolled 48 patients; 21 were treated with TACE-Apatinib and 27 with TACE-. Compared with TACE-Apatinib, TACE-

Topics: Adult; Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Portal Vein; Prognosis; Progression-Free Survival; Pyridines; Retrospective Studies; Time Factors; Venous Thrombosis

Hepatocellular carcinoma (HCC) is a highly invasive cancer associated with vascular invasion. The survival of advanced HCC is very poor. In this case study, we describe the efficacy and safety of apatinib in patient with advanced HCC as the first-line therapy.. A 46-year-old male complained of abdominal distention and pain for half a month.. HCC patient with portal vein and inferior vena cava tumor thrombus.. The apatinib alone was used as first-line therapy.. Intrahepatic tumors, portal vein, and inferior vena cava tumor thrombus were diminished. The patient achieved partial response (PR) soon after the treatment, and progression-free survival (PFS) was 12.5 months. During the entire process, the alpha-fetoprotein (AFP) continued to decrease.. Apatinib alone may be a safe and effective therapy for HCC patients with portal vein and inferior vena cava tumor thrombus. However, it is warranted further investigation in the future prospective randomized clinical studies.

Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Portal Vein; Pyridines; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis